Table of Contents
ISRN Endocrinology
Volume 2011 (2011), Article ID 803948, 8 pages
http://dx.doi.org/10.5402/2011/803948
Research Article

Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use

1Department of Paediatrics, Division of Endocrinology, Sophia Children’s Hospital/Erasmus University Medical Centre, 3015 GJ Rotterdam, The Netherlands
2Kinderzentrum am Johannis Platz, 04103 Leipzig, Germany
3Biopharm Medical Affairs, Novo Nordisk Health Care AG, Andreasstrasse 15, Oerlikon 8050, Zurich, Switzerland
4Clinical Research Department, Novo Nordisk Pharma GmbH, 55127 Mainz, Germany
5Goteborg Pediatric Growth Research Center, Institute for Clinical Sciences, Sahlgrenska Academy at Goteborg University, SE41345 Goteborg, Sweden

Received 12 April 2011; Accepted 11 June 2011

Academic Editor: W. C. Hymer

Copyright © 2011 Anita Hokken-Koelega et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Farber and J. R. Kerrigan, “The multiple indications for growth hormone treatment of pediatric patients,” Pediatric Annals, vol. 35, no. 12, pp. 926–932, 2006. View at Google Scholar · View at Scopus
  2. W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet, “Optimizing GH therapy in adults and children,” Endocrine Reviews, vol. 22, no. 4, pp. 425–450, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Cutfield, A. Lindberg, K. A. Wikland, P. Chatelain, M. B. Ranke, and P. Wilton, “Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS international board,” Acta Paediatrica, International Journal of Paediatrics, Supplement, vol. 88, no. 428, pp. 72–75, 1999. View at Google Scholar · View at Scopus
  4. P. M. Desrosiers, F. O'Brien, and S. Blethen, “Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth,” Pediatric Endocrinology Reviews, vol. 2, supplement 3, pp. 327–331, 2005. View at Google Scholar · View at Scopus
  5. S. L. Smith, P. C. Hindmarsh, and C. G. D. Brook, “Compliance with growth hormone treatment—are they getting it?” Archives of Disease in Childhood, vol. 68, no. 1, pp. 91–93, 1993. View at Google Scholar · View at Scopus
  6. E. Fidotti, “A history of growth hormone injection devices,” Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 5, pp. 497–501, 2001. View at Google Scholar · View at Scopus
  7. S. F. Ahmed, W. A. Smith, and C. Blamires, “Facilitating and understanding the family's choice of injection device for growth hormone therapy by using conjoint analysis,” Archives of Disease in Childhood, vol. 93, no. 2, pp. 110–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Dumas, P. Panayiotopoulos, D. Parker, and V. Pongpairochana, “Understanding and meeting the needs of those using growth hormone injection devices,” BioMed Central Endocrine Disorders, vol. 6, p. 5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. D. Gluckman and W. S. Cutfield, “Evaluation of a pen injector system for growth hormone treatment,” Archives of Disease in Childhood, vol. 66, no. 6, pp. 686–688, 1991. View at Google Scholar · View at Scopus
  10. J. Müller, N. E. Skakkebæk, B. B. Jacobsen et al., “Norditropin® SimpleXx(TM): a liquid human growth hormone formulation, a pen system and an auto-insertion device,” Hormone Research, vol. 51, supplement 3, pp. 109–112, 1999. View at Google Scholar
  11. J. Diglas, C. Feinböck, F. Winkler et al., “Reduced pain perception with Pen Mate(TM), an automatic needle insertion device for use with an insulin pen,” Practical Diabetes International, vol. 16, no. 2, pp. 39–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Oyarzabal, M. Aliaga, M. Chueca, G. Echarte, and A. Ulied, “Multicentre survey on compliance with growth hormone therapy: what can be improved?” Acta Paediatrica, vol. 87, no. 4, pp. 387–391, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Chan, “Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin,” Journal of Advanced Nursing, vol. 35, no. 6, pp. 882–892, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ida, N. Yoshimura, M. Nakacho et al., “Evaluation of the use of PenNeedle® 32G Taper in children being treated with growth hormone,” Clinical Pediatric Endocrinology, vol. 17, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Stanhope, A. Albanese, L. Moyle, and G. Hamill, “Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an auto injector and a pen injection system,” Archives of Disease in Childhood, vol. 67, no. 8, pp. 994–997, 1992. View at Google Scholar · View at Scopus
  16. K. M. Main, J. T. Jørgensen, N. T. Hertel, S. Jensen, and L. Jakobsen, “Automatic needle insertion diminishes pain during growth hormone injection,” Acta Paediatrica, vol. 84, no. 3, pp. 331–334, 1995. View at Google Scholar · View at Scopus
  17. R. R. Kapoor, S. A. Burke, S. E. Sparrow et al., “Monitoring of concordance in growth hormone therapy,” Archives of Disease in Childhood, vol. 93, no. 2, pp. 147–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Hunter, C. de Vries, T. M. A. MacDonald, and S. Greene, “Human growth hormone therapy: poor adherence equals poor growth,” Archives of Disease in Childhood, vol. 82, supplement 1, p. 28, 2000. View at Google Scholar
  19. B. P. N. Wickramasuriya, A. Casey, S. Akhtar et al., “Factors determining patient choice of device for GH therapy,” Hormone Research, vol. 65, no. 1, pp. 18–22, 2006. View at Publisher · View at Google Scholar · View at Scopus